Abstract
Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global myelodysplastic syndrome (MDS) therapeutic market. The report identifies the key trends shaping and driving the global MDS therapeutic market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MDS therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global myelodysplastic syndrome (MDS) market was valued at $652.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 12.2% to reach $1.5 billion by 2017. This growth forecast is primarily attributed to the currently approved drugs reaching their peak sales during the forecast period and secondarily due to a strong pipeline. The existing market is strong although with high unmet need. The market is represented by three approved drugs Vidaza (azacitidine), Dacogen (decitabine) and Revlimid (lenalidomide).
Scope
The report provides information on the key drivers and challenges of the MDS therapeutics market. Its scope includes -
• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) MDS therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HDCA (Histone deacetylase inhibitors) inhibitors, anti–CD33 mAb (monoclonal antibody) and VEGF (vascular endothelial growth receptor) inhibitors.
• Analysis of the current and future competition in the seven key countries MDS therapeutics market. Key market players covered are Amgen Inc, Arno Therapeutics, Array Biopharma, Cyclacel Pharmaceuticals Inc, Medac GmbH, Novartis AG, Onconova Therapeutics, Sanofi-Aventis, Synta Pharmaceuticals, S* BIO Pte, Telik Inc.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the MDS therapeutics market.
• Analysis of key recent licensing and partnership agreements in Myelodysplastic Syndrome Therapeutics market
Reasons To Buy
The report will enhance your decision making capability. It will allow you to -
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global MDS therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MDS therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global MDS therapeutics market landscape? – Identify, understand and capitalize.
Companies Mentioned
Amgen Inc.
Arno Therapeutics Inc.
Array Bippharma
Cyclacel Pharmaceuticals Inc.
Medac GmbH
Novartis AG
Onconova Therapeutics
Sanofi-Aventis
Synta Pharmaceuticals
S* BIO Pte
Telik Inc.
Table of Contents
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.6 Treatment
2.7 GlobalData Pipeline Report Guidance
3 Myelodysplastic Syndrome: Market Characterization
3.1 Major Markets, Market Size (2005-2010)
3.2 Major Markets, Market Forecast (2010-2017)
3.3 US Market Size (2005-2010)
3.4 US Market Forecast (2010-2017)
3.5 France Market Size (2005-2010)
3.6 France Market Forecast (2010-2017)
3.7 Germany Market Size (2005-2010)
3.8 Germany Market Forecast (2010-2017)
3.9 Italy Market Size (2005-2010)
3.10 Italy Market Forecast (2010-2017)
3.11 Spain Market Size (2005-2010)
3.12 Spain Market Forecast (2010-2017)
3.13 UK Market Size (2005-2010)
3.14 UK Market Forecast (2010-2017)
3.15 Japan Market Size (2005-2010)
3.16 Japan Market Forecast (2010-2017)
3.17 Drivers and Barriers for Myelodysplastic Syndrome Therapeutic Market
3.17.1 Drivers for Myelodysplastic Syndrome Market
3.17.2 Barriers for Myelodysplastic Syndrome Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Myelodysplastic Syndrome Market: Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Myelodysplastic Syndrome Market Marketed Products Profile
4.2.1 Vidaza (azacytidine)
4.2.2 Dacogen (decitabine)
4.2.3 Revlimid (lenalidomide)
4.3 Key Takeaway
5 Myelodysplastic Syndrome: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Myelodysplastic Syndrome Pipeline Analysis – Pipeline by Clinical Phases of Development
5.3.1 Myelodysplastic Syndrome Therapeutics – Phase III Clinical Pipeline
5.3.2 Myelodysplastic Therapeutics – Phase II Clinical Pipeline
5.3.3 Myelodysplastic Syndrome Therapeutics – Phase I Clinical Pipeline
5.3.4 Myelodysplastic Syndrome Therapeutics – Preclinical Pipeline
5.4 Myelodysplastic Syndrome Pipeline by Mechanism of Action
5.5 Myelodysplastic Syndrome Technology Trends Analytical Framework
5.6 Myelodysplastic Syndrome Clinical Pipeline by Monotherapy and Combination Therapy
5.7 Myelodysplastic Syndrome Therapeutics – Promising Drugs under Clinical Development
5.8 Molecule Profile for Promising Drugs under Clinical Development
5.8.1 Treosulfan
5.9 Key Takeaway
6 Myelodysplastic Syndrome Therapeutics – Clinical Trials Mapping
6.1 Clinical Trials Mapping by Region/Country
6.2 Clinical Trials Mapping by Phase
6.3 Clinical Trials Mapping by Trial Status
6.4 Clinical Trials Mapping by Prominent Sponsors
6.5 Participants in Therapeutic Clinical Trials - Companies
7 Myelodysplastic Syndrome Therapeutics: Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Global Myelodysplastic Syndrome Therapeutics: Future Players in The Market
8.1 Introduction
8.2 Amgen Inc.
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Business Overview
8.3 Arno Therapeutics Inc.
8.3.1 Company Overview
8.3.2 Business Overview
8.4 Array Bippharma
8.4.1 Company Overview
8.5 Cyclacel Pharmaceuticals Inc.
8.5.1 Company Overview
8.6 Medac GmbH
8.6.1 Company Overview
8.7 Novartis AG
8.8 Onconova Therapeutics
8.8.1 Company Overview
8.9 Sanofi-Aventis
8.9.1 Company Overview
8.9.2 Financial Overview
8.9.3 Business Description
8.10 Synta Pharmaceuticals
8.10.1 Company Overview
8.10.2 Financial Overview
8.10.3 Business Overview
8.11 S* BIO Pte
8.11.1 Company Overview
8.12 Telik Inc.
8.12.1 Company Overview
8.12.2 Financial Overview
8.12.3 Business Overview
8.13 Other Companies in Pipeline – Tabular Presentation
9 Licensing and Partnership Deals
10 Global Myelodysplastic Syndrome Market: Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panels
10.4 Contact Us
10.5 Disclaimer
10.6 Sources
List of Tables
1.1 List of Tables
Table 1: French-British-American Classification of MDS
Table 2: World Health Organisation Classification of MDS
Table 3: IPSS Point Chart for MDS
Table 4: IPSS Classification Chart for MDS
Table 5: MDS Therapeutics, Global, Market Revenue ($m), 2005-2010
Table 6: MDS Therapeutics, Global, Revenue Forecasts ($m), 2010-2017
Table 7: MDS Therapeutics, US, Market Historical Revenue ($m), 2005-2010
Table 8: MDS Therapeutics, US, Revenue Forecasts ($m), 2010-2017
Table 9: MDS Therapeutics, France, Market Revenue ($m), 2005-2010
Table 10: MDS Therapeutics, France, Revenue Forecasts ($m), 2010-2017
Table 11: MDS Therapeutics, Germany, Market Revenue ($m), 2005-2010
Table 12: MDS Therapeutics, Germany, Revenue Forecasts ($m), 2010-2017
Table 13: MDS Therapeutics, Italy, Market Revenue ($m), 2005-2010
Table 14: MDS Therapeutics, Italy, Revenue Forecasts ($m), 2010-2017
Table 15: MDS Therapeutics, Spain, Market Revenue ($m), 2005-2010
Table 16: MDS Therapeutics, Spain, Revenue Forecasts ($m), 2010-2017
Table 17: MDS Therapeutics, the UK, Market Revenue ($m), 2005-2010
Table 18: MDS Therapeutics, the UK, Revenue Forecasts ($m), 2010-2017
Table 19: MDS Therapeutics, Japan, Market Revenue ($m), 2005-2010
Table 20: MDS Therapeutics, Japan, Revenue Forecasts ($m), 2010-2017
Table 21: MDS Therapeutics – Phase III Clinical Pipeline, 2011
Table 22: MDS Therapeutics – Phase II Clinical Pipeline, 2011
Table 23: MDS Therapeutics – Phase I Clinical Pipeline, 2011
Table 24: MDS Therapeutics – Preclinical Pipeline, 2011
Table 25: Mechanism of Action That Constitute the Others in the Above Pie Chart
Table 26: MDS Therapeutics – Promising Drugs Under Clinical Development, 2011
Table 27: MDS Clinical Trials by Region – Number, 2011
Table 28: MDS Clinical Trials by Phase and Country, 2011
Table 29: MDS Clinical Trials by Status and Country, 2011
Table 30: MDS Clinical Trials by Sponsors and Country, 2011
Table 31: MDS Clinical Trials by Prominent Sponsors, 2011
Table 32: Amgen – Promising Molecules in Pipeline for Oncology, 2011
Table 33: Amgen Inc, Deals 2009-2011
Table 34: Arno Therapeutics – Promising Molecules in Pipeline for Oncology, 2011
Table 35: Array Biopharma – Promising Molecules in Pipeline for Oncology, 2011
Table 36: Array Biopharma Deals, 2009-2011
Table 37: Cyclacel Pharma – Promising Molecules in Pipeline for Oncology, 2011
Table 38: Medac GmbH – Promising Molecules in Pipeline for Oncology, 2011
Table 39: Medac GmbH Deals, 2009-2011
Table 40: Novartis – Oncology Pipeline, 2010
Table 41: Novartis Deals, 2009-2010
Table 42: Onconova Therapeutics – Promising Molecules in Pipeline for Oncology, 2011
Table 43: Onconova Therapeutics Deals, 2009-2011
Table 44: Sanofi-Aventis – Promising Molecules in Pipeline for Oncology, 2011
Table 45: Sanofi-Aventis Key Deals, 2010-2011
Table 46: Synta Pharmaceuticals – Promising Molecules in Pipeline for Oncology, 2011
Table 47: Synta Pharmaceuticals Deals, 2009-2011
Table 48: S* BIO Pte – Promising Molecules in Pipeline for Oncology, 2011
Table 49: Telik – Promising Molecules in Pipeline for Oncology, 2011
Table 50: Other Companies that have Molecules for MDS in Pipeline
Table 51: MDS Therapeutics, Licensing and Partnership Deals
List of Figures
1.2 List of Figures
Figure 1: MDS Therapeutics, Global, Market Revenue ($m), 2005-2010
Figure 2: MDS Therapeutics, Market Share ($m, %), 2010
Figure 3: MDS Therapeutics, Global, Revenue Forecasts ($m), 2010-2017
Figure 4: MDS Therapeutics, Forecast Market Share ($m, %), 2017
Figure 5: MDS Therapeutics, US, Market Revenue ($m), 2005-2010
Figure 6: MDS Therapeutics, US, Revenue Forecasts ($m), 2010-2017
Figure 7: MDS Therapeutics, France, Market Revenue ($m), 2005-2010
Figure 8: MDS Therapeutics, France, Revenue Forecasts ($m), 2010-2017
Figure 9: MDS Therapeutics, Germany, Market Revenue ($m), 2005-2010
Figure 10: MDS Therapeutics, Germany, Revenue Forecasts ($m), 2010-2017
Figure 11: MDS Therapeutics, Italy, Market Revenue ($m), 2005-2010
Figure 12: MDS Therapeutics, Italy, Revenue Forecasts ($m), 2010-2017
Figure 13: MDS Therapeutics, Spain, Market Revenue ($m), 2005-2010
Figure 14: MDS Therapeutics, Spain, Revenue Forecasts ($m), 2010-2017
Figure 15: MDS Therapeutics, the UK, Market Revenue ($m), 2005-2010
Figure 16: MDS Therapeutics, the UK, Revenue Forecasts ($m), 2010-2017
Figure 17: MDS Therapeutics, Japan, Market Revenue ($m), 2005-2010
Figure 18: MDS Therapeutics, Japan, Revenue Forecasts ($m), 2010-2017
Figure 19: Opportunity and Unmet Need in the MDS Therapeutic Market
Figure 20: Strategic Competitor Assessment of Marketed Products for MDS, 2010
Figure 21: Pipeline Products by Phase of Clinical Development, 2011
Figure 22: MDS Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 23: MDS Market – Clinical Pipeline by Mechanism Of Action, 2011
Figure 24: Technology Trends Analytical Framework of The MDS Pipeline, 2011
Figure 25: Technology Trends Analytical Framework of The MDS Pipeline - Description, 2011
Figure 26: MDS pipeline by The Nature of Therapy, 2011
Figure 27: MDS Clinical Trials by Region, 2011
Figure 28: MDS Clinical Trials by Phase, 2011
Figure 29: MDS Clinical Trials by Status, 2011
Figure 30: MDS Clinical Trials by Sponsors, 2011
Figure 31: MDS Clinical Trials by Prominent Sponsors, 2011
Figure 32: MDS Therapeutic Clinical Trial - Company Sponsors by Phase, 2011
Figure 33: MDS Therapeutics, Key Events Impacting Future Market
Figure 34: MDS Therapeutics, Strategic Assessment, 2011
Figure 35: MDS Therapeutics, Clinical Pipeline by Company, 2011
Figure 36: GlobalData market Forecasting Model, 2011
